Regulatory Uncertainty and Data Limitations Justify Hold Rating and Constrained Upside for Outlook Therapeutics

H.C. Wainwright analyst Douglas Tsao reiterated a Hold rating on Outlook Therapeutics today and set a price target of $0.50.

Douglas Tsao has given his Hold rating due to a combination of factors related to Outlook Therapeutics’ regulatory and clinical outlook. He believes the formal dispute resolution request with the FDA is unlikely to overturn prior complete response letters in a timely way, particularly given the historically low success rate of such appeals and the weaknesses in the current Lytenava data package. The failure of the NORSE EIGHT trial to meet its primary endpoint and the reliance on a non–pre-specified 12‑week analysis undermines the strength of the company’s argument that existing results should suffice for approval.

At the same time, the FDRR may at least provide clarity on what additional confirmatory evidence the FDA would require, which is important given Outlook’s limited cash runway into June. Tsao also notes that while the NORSE 2 study was positive and considered adequate, its design and comparator may not satisfy the agency’s latest standards for wet AMD drugs, implying potentially significant additional work and cost. His $0.50 price target reflects modest risk‑adjusted revenue expectations and a view that upside is constrained by regulatory uncertainty and concentration in a single development asset.

According to TipRanks, Tsao is a 5-star analyst with an average return of 17.3% and a 48.09% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Xenon, and Rezolute.

In another report released on March 26, TipRanks – xAI also reiterated a Hold rating on the stock with a $0.19 price target.